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JapanPeripheral Blood as a Preferable Source of Stem Cells
for Salvage Transplantation in Patients with Graft
Failure after Cord Blood Transplantation: A
Retrospective Analysis of the Registry Data
of the Japanese Society for Hematopoietic
Cell Transplantation
Shigeo Fuji,1,2 Fumiaki Nakamura,2,3 Kazuo Hatanaka,2,4 Shuichi Taniguchi,5 Maho Sato,6
Shin-ichiro Mori,7 Hisashi Sakamaki,8 Hiromasa Yabe,9 Toshihiro Miyamoto,10
Heiwa Kanamori,11 Yasunori Ueda,12 Keisei Kawa,6 Koji Kato,13 Ritsuro Suzuki,14
Yoshiko Atsuta,14 Toshiharu Tamaki,15 Yoshinobu Kanda16To compare the different stem cell sources used in salvage transplantation for graft failure (GF) after cord blood
transplantation (CBT), we retrospectively analyzed data of 220 patients who developed GF after undergoing
CBT between January 2001 and December 2007 and underwent a second hematopoietic stem cell transplan-
tation (HSCT) within 3 months. The donor sources for salvage HSCTwere cord blood (n5 180), peripheral
blood stem cells (PBSCs; n5 24), and bone marrow (BM; n5 16). The cumulative incidence of neutrophil en-
graftment on day 30 after the second HSCTwas 39% with CB, 71% with PBSCs, and 75% with BM. Multivariate
analysis revealed that PBSC and BM grafts were associated with a significantly higher engraftment rate than CB
(hazard ratio [HR], 7.77; P\.001 and HR, 2.81; P 5 .016, respectively). Although the incidence of grade II-IV
acute graft-versus-host disease was significantly higher in the PBSC group than in the CB group (HR, 2.83;
P 5 .011), the incidence of 1-year nonrelapse mortality was lower in the PBSC group than in the CB group
(HR, 0.43; P5 .019), and 1-year overall survival was superior in the PBSC group compared with the CB group
(HR, 0.45; P5.036). Our results suggest that PBSC is the preferable source of stem cells in salvageHSCT forGF
after CBT.
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1408 Biol Blood Marrow Transplant 18:1407-1414, 2012S. Fuji et al.regimens. The GF rate after HSCT with conventional
myeloablative conditioning (CST) regimens is\5%
for peripheral blood stem cell transplantation
(PBSCT), 5%-10% for bone marrow transplanta-
tion (BMT), and 20% for CBT [2-5]. Rocha et al.
[4] reported GF rates of 10% for unrelated BMT
and 22% for CBT. Atsuta et al. [5] reported GF rates
of 6% and 23% in patients with acute myelogenous
leukemia (AML) treated with unrelated BMT and
CBT, respectively, and corresponding GF rates of
3% and 20% in patients with acute lymphoblastic leu-
kemia (ALL). These results indicate that GF is not
a rare complication.
The survival rate of patients who developedGF after
allogeneic HSCT but did not undergo a second salvage
transplantation has been \10% [4-6]. In a recent
investigation of the feasibility of a second HSCT with
an RIC regimen for GF, Guardiola et al. [7] reported
the clinical outcomes of 82 patients withGFwho under-
went a second transplantation, most from an HLA-
matched sibling donor. The 3-year overall survival
(OS) rate in these patients was 30%, significantly better
than that reported in a previous study in which the pa-
tients did not undergo a second HSCT. Waki et al. [8]
analyzed the clinical outcomes of 80 patients with GF
who underwent salvage CBT and found a 1-year OS
rate of 33%, with nonrelapse mortality (NRM), espe-
cially infectious diseases, as the major cause of death
[8]. This OS rate was higher than that reported in a pre-
vious study in which patients did not undergo a second
HSCT; however, the low engraftment rate and high
NRM rate after salvage CBT are not acceptable results.
Schriber et al. [9] obtained clinical data of 122 patients
who underwent unrelated HSCT as salvage treatment
for GF from the database of National Marrow Donor
Program. The engraftment rate of 74% in this series
was markedly greater than that reported by Waki et al.
[8], possibly attributable to differences in stem cell sour-
ces.However, the high engraftment rate did not improve
the outcome because of a high NRM rate (86%). Infec-
tious disease was the major cause of death in that study.
Given that infectious diseases are a main cause of
failure after secondHSCT, peripheral blood stem cells
(PBSCs) may be the preferred stem cell source for the
second transplantation. However, acute and chronic
graft-versus-host disease (GVHD) is a concern after
PBSCT, especially after HLA-mismatched transplan-
tation. The effect of the stem cell source in a second
HSCT has not yet been clarified, because previous
studies had insufficient statistical power to analyze
the effect of this factor using multivariate analysis.
In the present study, we retrospectively analyzed
the clinical outcomes of patients who had undergone
salvage HSCT after GF, using registry data of the
Japanese Society for Hematopoietic Cell Transplanta-
tion (JSHCT). We compared outcomes by stem cell
source:PBSCs, cord blood (CB), or bonemarrow (BM).MATERIALS AND METHODS
Patients
This study was approved by the Institutional Re-
view Board of Izumisano Municipal Hospital, Rinku
General Medical Center, Osaka, Japan. The patients’
clinical data were obtained from the JSHCT database
[10]. The following patients were included in the
study: (1) patients who developed primary or second-
ary GF after allogeneic HSCT performed between
January 2000 and December 2007, (2) patients who
underwent a second HSCT for GF within 3 months
after the diagnosis of GF, and (3) patients who did
not demonstrate progression of the primary disease
before the second HSCT. Neutrophil engraftment
was defined as an absolute neutrophil count (ANC)
.500/mm3 in the first 3 consecutive days after
HSCT. Primary GF was defined in accordance with
a previous report as an ANC not exceeding 500/mm3
or the absence of donor T cells (\5%) before relapse,
disease progression, second HSCT, or death [11]. Sec-
ondary GF was defined as a decrease in ANC of\100/
mm3 at 3 determinations or absence of donor T cells
(\5%) after the initial engraftment without recovery
before relapse, disease progression, second HSCT,
or death. Chimerism was assessed using polymerase
chain reaction for short tandem repeats or variable
number tandem repeats. Sex chromosome chimerism
in sex-mismatched donor–recipient pairs was assessed
using fluorescence in situ hybridization.
Data of 382 patients were obtained from the
JSHCT database. Of these 382 patients, 67 were
excluded because of relapse or disease progression be-
fore the second HSCT, autologous hematopoietic
recovery, autologous HSCT, or missing data on, for
example, stem cell source, engraftment, and OS. Fur-
thermore, patients who received PBSCs (n 5 24) or
BM (n 5 71) for the first HSCT were excluded, to
focus on CBT in this study. The data of the remaining
220 patients were subjected to further analysis.Statistical Analysis
We first performed a statistical analysis of the dif-
ferences in the 3 stem cell sources. Patients and trans-
plantation characteristics in the different groups were
compared using the c2 test to determine the difference
in proportions. One-way analysis of variance was used
to compare mean values. The primary endpoint of
this study was the engraftment rate after second
HSCT. Secondary endpoints included the probabili-
ties of OS and progression-free survival (PFS) and
the cumulative incidents of NRM, acute GVHD, and
infectious diseases after the second HSCT. OS and
PFS were estimated using the Kaplan-Meier method.
The cumulative incidents of engraftment, relapse,
GVHD, and infectious diseases were evaluated using
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engraftment, relapse, GVHD, and infectious diseases,
death before these events was defined as a competing
risk. The competing-risk regression model of Fine
andGrey was used for univariate andmultivariate anal-
yses of cumulative incidence. A Cox proportional haz-
ards regression model was used to analyze OS and
PFS. Factors associated with a 2-sided P value of
\.10 in the univariate analysis were included in a mul-
tivariate analysis. A backward-stepwise selection algo-
rithm was used, and only the statistically significant
variables were retained in the final model. A 2-sided
P value of\.05 was considered statistically significant.
The following variables were evaluated in these
analyses: sex, age at time of HSCT, disease risk (stan-
dard risk versus high risk), conditioning regimen for
the first HSCT (CST versus RIC versus nonmyeloa-
blative [NMA]), conditioning regimen for the second
HSCT (CST versus RIC versus NMA), use of fludar-
abine (Flu), use of an alkylator-containing regimen,
use of total body irradiation (TBI), use of antithymo-
cyte globulin (ATG), stem cell source (PBSCs, BM,
or CB) for the second HSCT, immunosuppressive
drugs (primary drug: none, cyclosporine, or tacrolimus
[TAC]; secondary drug: methotrexate [MTX], myco-
phenolate mofetil [MMF], neither MTX nor MMF,
steroid, or no steroid), HLA disparities (in both
graft-versus-host and host-versus-graft directions),
and type of GF (primary versus secondary). Standard
risk was defined as the first complete remission of acute
leukemia or malignant lymphoma, the first chronic
phase of chronic myelogenous leukemia, or nonmalig-
nant disease. High risk was defined as other stages of
hematologic malignancies and solid tumors. The defi-
nitions of conditioning regimens were similar to
those used in previous studies [12,13]. Myeloablative
conditioning regimens included at least 1 of the
following: .8 Gy TBI, .140 mg/m2 melphalan, or
.6.4 mg/m2 i.v. busulfan (or .8.0 mg/m2 oral
busulfan). NMA conditioning included conditioning
regimens with 2 Gy TBI plus a purine analogue,
Flu 1 cyclophosphamide 1 ATG, Flu 1 cytarabine 1
idarubicin, cladribine 1 cytarabine, or total
lymphoid irradiation 1 ATG. RIC included all other
conditioning regimens. Infectious diseases included
both clinically and microbiologically documented
infections diagnosed by a physician. Statistical
analyses were performed using Stata version 11.1
(StataCorp, College Station, TX).RESULTS
Patients
Recipient and transplantation characteristics are
summarized in Table 1. Because of the limited avail-
ability of stem cell grafts in Japan, all CB recipients re-ceived only single CB unit. The median age of the
recipients was 42.5 years (range, 0-75 years). Their di-
agnoses included AML (n 5 71), ALL (n 5 40), mye-
lodysplastic syndrome (MDS; n 5 52), malignant
lymphoma (n 5 31), nonmalignant diseases (n 5 14),
and others (n 5 12). Eighty-two patients were classi-
fied as standard risk, and 138 were classified as high
risk. The conditioning regimen at the first HSCT
was CST in 137 patients, RIC in 80 patients, and
NMA in 2 patients. Of the 220 patients who had GF,
200 (90.9%) had primary GF and 19 (8.7%) had sec-
ondary GF. In these 220 patients, GF was diagnosed
after a median of 29 days (range, 12-176) after the first
HSCT.
The median interval between the diagnosis of GF
and the second HSCT was 11 days (range, 0-89
days). The stem cell source for the second HSCT
was CB in 180 patients, BM in 16 patients, and PBSCs
in 24 patients. In the BM and PBSC recipients, all
except 1 patient with BM received stem cells from
a related donor. The patients who underwent PBSCT
received stem cells from an HLA 1-locus mismatched
donor (n5 1; 4.5%) or a haploidentical donor (n5 21;
95.5%). The patients undergoing BMT received stem
cells from an HLA-matched donor (related, n5 2; un-
related, n5 1) or an HLA 1-locus mismatched (n5 2;
12.5%) or haploidentical donor (n 5 11; 68.8%). For
conditioning, 5, 122 and 77 patients received CST,
RIC and NMA, respectively. As for GVHD, prophy-
laxis included cyclosporine in 79 patients, TAC in
118 patients, and ATG in 38 patients. A short course
of MTX was added in 57 patients, and a short course
of MMF was added in 21 patients. No patient received
posttransplantation cyclophosphamide as GVHDpro-
phylaxis.Neutrophil Engraftment
The cumulative incidents of neutrophil engraft-
ment according to stem cell source are shown in
Figure 1. Engraftment was achieved by day 30 after
second HSCT in 39% of CBT recipients, 71% of
PBSCT recipients, and 75% of BMT recipients. En-
graftment was achieved at median intervals of 21
days (range, 12-97) after CBT, 18 days (range, 0-37
days) after PBSCT, and 14.5 days (range, 9-26 days) af-
ter BMT. In the univariate analysis, PBSCT and BMT
were associated with a significantly higher probability
of engraftment (hazard ratio [HR], 2.5; 95% confi-
dence interval [CI], 1.5-4.3; P 5 .001 and HR, 2.5;
95% CI, 1.2-5.0; P 5 .01, respectively). In the
multivariate analysis, PBSCT and BMT remained
significant variables after adjustment for other inde-
pendently significant variables, including the use of al-
kylating agents, HLA disparities, and administration
of additional immunosuppressive drugs (Table 2).
Table 1. Patient and Transplantation Characteristics
CB BM PBSCs Total P Value
Number of patients 180 16 24 220
Conditioning regimen
for first HSCT, n
CST 114 9 14 137
RIC 63 7 10 80
NMA 2 0 0 2
Unknown 1 0 0 1 .968
Sex of recipient, n
Male 97 13 11 121
Female 83 3 13 99 .069
Age of recipient, years,
median
44 14 28.5 42.5 .0016
ABO mismatch, n
Match 57 6 12 75
Minor 42 3 5 50
Major 51 4 3 58
Major/minor 29 0 3 32
Unknown 1 3 1 5 <.001
HLA disparities
(graft-versus-host
direction), n
0 22 3 0 25
1 59 2 1 62
2 96 9 13 118
3 2 2 8 12
Unknown 1 0 2 3 <.001
HLA disparities
(host-versus-graft
direction), n
0 14 5 0 19
1 60 2 4 66
2 102 7 8 117
3 3 2 10 15
Unknown 1 0 2 3 <.001
Disease risk, n
0 65 6 11 82
1 115 10 13 138 .652
Disease, n
ALL 30 4 6 40
AML 59 3 9 71
MDS 45 5 2 52
Chronic myelogenous
leukemia
6 1 1 8
Lymphoma 28 0 3 31
Plasma cell disorder 1 0 0 1
Nonhematologic
malignancies
2 0 1 3
Nonmalignant disease 9 3 2 14 .402
Conditioning regimen, n
None 10 1 2 13
CST 4 1 0 5
RIST 105 8 9 122
Mini 60 6 11 77
Unknown 1 0 2 3 .074
TBI, n
No 123 13 17 153
Yes 56 2 4 62
Unknown 1 1 3 5 .001
Alkylating agent, n
No 59 5 7 71
Yes 120 10 14 144
Unknown 1 1 3 5 .005
Flu/cladribine, n
No 22 2 3 27
Yes 157 13 18 188
Unknown 1 1 3 5 .005
Calcineurin inhibitor, n
None 13 0 2 15
Cyclosporine 76 1 2 79
TAC 84 15 19 118
Unknown 7 0 1 8 .053
(Continued )
Table 1. (Continued )
CB BM PBSCs Total P Value
Additional
immunosuppressive
drugs, n
None 122 4 8 134
MTX 32 12 13 57
MMF 19 0 2 21
Unknown 7 0 1 8 <.001
Steroids, n
No 160 13 18 191
Yes 13 3 5 21
Unknown 7 0 1 8 .147
ATG, n
None 153 11 13 177
Yes 26 4 8 38
Unknown 1 1 3 5 <.001
Engraftment failure of
previous
transplantation, n
Primary 162 16 22 200
Secondary 17 0 2 19
Unknown 1 0 0 1 <.001
Time from graft failure
to transplantation,
days, median (range) 12 (0-89) 7 (0-83) 9 (0-34) 11 (0-89) .115
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and BMT.
OS and PFS
The median follow-up period for surviving
patients after second HSCT was 481 days (range, 82-
1825 days). The probability of 1-year OS after the sec-
ond HSCT was 58% with PBSCs, 38% with BM, and
28% with CB (Figure 2A). In the multivariate analysis,
after adjustment for age, disease risk, use of calcineurin
inhibitors, and use of steroids in GVHD prophylaxis,
the probability of 1-year OS was significantly greater
after PBSCT than after CBT (HR, 0.45; 95% CI,
0.21-0.95; P5 .036). The probability of 1-year PFS af-
ter the second HSCTwas 48%with PBSCs, 34% with
BM, and 24% with CB (Figure 2B). After adjustmentFigure 1. Cumulative incidence of engraftment after a second HSCT in
patients according to stem cell source.
Table 2. Multivariate Analysis for Engraftment, OS, and PFS
HR (95% CI) P Value
Engraftment
Stem cell source
CB Reference
BM 2.81 (1.21-6.53) .016
PBSCs 7.77 (4.16-14.51) <.001
Alkylating agent
None Reference
Yes 2.69 (1.64-4.41) <.001
HLA disparities (host-versus-graft
direction)
0 Reference
1 0.47 (0.22-1.03) .06
2 0.46 (0.22-0.97) .041
3 0.21 (0.08-0.61) .004
Additional immunosuppressive drugs
None Reference
MTX 0.19 (0.06-0.63) .006
MMF 0.99 (0.66-1.48) .945
OS
Stem cell source
CB Reference
BM 0.95 (0.46-1.95) .881
PBSCs 0.45 (0.21-0.95) .036
Disease risk
Normal Reference
High 1.74 (1.21-2.49) .003
Steroids
None Reference
Yes 2.31 (1.37-3.91) .002
Each additional year older 1.01 (1.00-1.02) .003
Calcineurin inhibitor
Cyclosporine Reference
None 0.97 (0.53-1.75) .915
TAC 0.63 (0.44-0.90) .011
PFS
Stem cell source
CB Reference
BM 0.95 (0.46-1.96) .886
PBSCs 0.52 (0.25-1.05) .066
Disease risk
Normal Reference
High 1.85 (1.29-2.66) .001
Calcineurin inhibitor
Cyclosporine Reference
None 0.99 (0.55-1.79) .971
TAC 0.61 (0.43-0.88) .008
Steroids
None Reference
Yes 2.01 (1.19-3.40) .009
Each additional year older 1.01 (1.00-1.02) .014
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use of steroid as GVHD prophylaxis, the multivariate
analysis indicated a trend toward a higher probability
of 1-year PFS after PBSCT than after CBT (HR,
0.52; 95% CI, 0.25-1.05; P 5 .066) (Table 2). There
were no statistically significant differences in OS and
PFS between recipients of BMT and recipients of
CBT.
NRM and Transplantation-Related
Complications
The cumulative incidence of NRM at 1 year after
the second HSCT was 29% with PBSCs, 38% with
BM, and 60% with CB (Figure 2C). After adjustmentfor age and use of steroids, the incidence of 1-year
NRM was significantly lower after PBSCT than after
CBT (HR, 0.43; 95% CI, 0.21-0.87; P 5 .019). The
cumulative incidents of grade II-IV acute GVHD
were 47% after PBSCT, 31% after BMT, and 19% af-
ter CBT (Figure 2D), and the corresponding cumula-
tive incidents of grade III-IV acute GVHD were 44%,
0%, and 12% (Figure 2E). After adjustment for the use
of TBI in multivariate analysis, PBSCT was associated
with a significantly higher incidence of grade II-IV
(HR, 2.8; 95% CI, 1.3-6.3; P 5 .011) (Table 3). After
adjustment for the use of steroids as GVHD
prophylaxis and the type of conditioning regimen in
multivariate analysis, PBSCT was associated with
a significantly higher incidence of grade III-IV (HR,
7.3; 95% CI, 2.9-18.7; P\ .001).
The cumulative incidents of infectious disease at 1
year after the second HSCT were 23% with PBSC,
15% with BM, and 58% with CB (Figure 3). PBSCT
and BMTwere associated with a significantly lower in-
cidence rate of infectious disease (HR, 0.33; 95% CI,
0.14-0.81; P 5 .015 and HR, 0.21; 95% CI, 0.05-
0.87; P 5 .032, respectively). The significant risk fac-
tors in the multivariate analyses are listed in Table 3.
The major cause of death in our cohort was infectious
disease (n 5 72); other causes of death were relapse or
progression of primary disease (n 5 31), organ failure
(n 5 26), acute GVHD (n 5 8), and others (n 5 15).DISCUSSION
In this study, we retrospectively analyzed the out-
comes of 220 patients who underwent a second alloge-
neic HSCT after GF. The largest sample size found in
the literature allowed us to analyze the effect of stem
cell source on outcome. Neutrophil engraftment was
significantly faster after PBSCT and BMT than after
CBT. Patients with GF are at increased risk for devel-
oping a lethal infectious disease because of prolonged
severe pancytopenia, and thus the faster neutrophil
recovery after PBSCT and BMT is a highly beneficial
effect. The differences in engraftment rate of stem cells
from different sources in the present study may be
greater than those observed after the firstHSCT in pre-
vious studies [2-5], possibly because many patients died
before engraftment after the second CBT. Infectious
disease was the main cause of death in our cohort.
The clinical outcomes after salvage CBT in the
present study are comparable to those reported by
Waki et al. [8]. The 1-year OS was 28% in the present
study and 33% in the study ofWaki et al. The engraft-
ment rate was lower in our cohort; however, this differ-
ence may be attributable to the fact that Waki et al.
excluded patients who died before engraftment within
28 days after second HSCT. Our engraftment rate af-
ter PBSCT was comparable to that reported in the
Figure 2. Probability of 1-year OS (A), probability of 1-year PFS (B), cumulative incidence of NRM (C), cumulative incidence of grade II-IV acute GVHD
(D), and cumulative incidence of grade III-IV acute GVHD (E) in patients according to stem cell source.
1412 Biol Blood Marrow Transplant 18:1407-1414, 2012S. Fuji et al.previous NMDP study, but our OS was greater [9].
The poor OS in the NMDP study might be attribut-
able to the longer interval between the diagnosis of
GF and the second HSCT (median, 48 days) because
they included only patients who underwent unrelated
HSCT, which takes more time to coordinate. In addi-
tion, the proportion of patients who received a conven-
tional conditioning regimen was significantly higher in
the NMDP study than in the present study, possibly
contributing to the higher NRM rate in the NMDP
study [14]. Most patients in the present study received
an RIC or NMA regimen, which might have reduced
the incidence of NRM.
The risk of severe GVHD is a major concern when
selecting HLA-mismatched PBSCs as the stem cell
source for a second HSCT, even with the advantage
of faster engraftment. In fact, PBSCT was associated
with significantly higher rates of grade II-IV and grade
III-IV acute GVHD, as expected given that the major-
ity of PBSC grafts were obtained from HLA-
mismatched donors. The incidence rate of NRM was
significantly lower after PBSCT, however. In addition,
21 of 22 PBSCT recipients with available HLA infor-
mation (95%) received stem cells from a 2-3 HLA
antigen-mismatched donor. The main cause of deathafter second HSCT, especially before engraftment,
was infectious disease; therefore, an early, significant
reduction in the rate of infectious disease after the sec-
ond HSCT contributed to the reduction in NRM. In
addition, our study cohort comprised exclusively
Japanese patients, who have a lower incidence of acute
GVHD compared with Caucasian patients and can
better tolerate HLA-mismatched HSCT without
ex vivo T cell depletion [15-17]. The superiority of
PBSC compared with CB awaits confirmation in
Caucasian patients.
Regarding the conditioning regimen for salvage
PBSCT, we performed univariate analysis only be-
cause of the limited number of patients. The cumula-
tive incidents of engraftment were 100% with a
Flu-based regimen including an alkylator, 78% with
a Flu-based regimen without an alkylator, and 0%
without any conditioning regimen. The use of a Flu-
based regimen including an alkylator was associated
with a significantly higher probability of engraftment
compared with a Flu-based regimen without an alkyla-
tor (HR, 4.5; 95%CI, 1.6-12.8; P5 .0051). The prob-
ability of 1-yearOSwas 82%with a Flu-based regimen
including an alkylator, but only 44% with a Flu-based
regimen without an alkylator (P 5 .27). Alkylators
Table 3. Multivariate Analysis for NRM, Acute GVHD, and
Infectious Disease
HR (95% CI) P Value
NRM
Stem cell source
CB Reference
BM 0.54 (0.25-1.15) .111
PBSCs 0.43 (0.21-0.87) .019
Steroids
None Reference
Yes 2.41 (1.59-3.66) <.001
Each additional year older 1.01 (1.00-1.02) .015
Grade II-IV acute GVHD
Stem cell source
CB Reference
BM 1.74 (0.54-5.62) .352
PBSCs 2.83 (1.27-6.27) .011
TBI
None Reference
Yes 2.43 (1.29-4.61) .006
Grade III-IV acute GVHD
Stem cell source
CB Reference
BM <0.01 <.001
PBSCs 7.34 (2.87-18.74) <.001
Steroids
None Reference
Yes <0.01 <.001
Conditioning regimen
None Reference
CST 16.12 (1.34-193.80) .028
RIST 1.93 (0.20-18.75) .573
Mini 0.94 (0.09-9.60) .961
All infectious diseases
Stem cell source
CB Reference
BM 0.21 (0.05-0.87) .032
PBSCs 0.33 (0.14-0.81) .015
Additional immunosuppressive
drugs
None Reference
MTX 1.09 (0.64-1.85) .748
MMF 2.25 (1.23-4.10) .008
Disease risk
Normal Reference
High 0.63 (0.41-0.98) .039
Figure 3. Cumulative incidence of infectious disease in patients
according to stem cell source.
Biol Blood Marrow Transplant 18:1407-1414, 2012 1413Salvage SCT for Graft Failure after CBTincluded cyclophosphamide in 7 patients and melpha-
lan in 3 patients. The majority of patients (79%) re-
ceived TAC-based GVHD prophylaxis. Therefore,
PBSCT with a Flu 1 alkylator combination regimen
followed by TAC-based GVHD prophylaxis seemed
to be the preferable course of treatment.
Some limitations of this study warrant considerea-
tion. A major limitation is the study’s retrospective
nature and use of registry data, which make it impossi-
ble to identify the decisions made by the physicians
regarding stem cell source, conditioning regimen, tim-
ing of second HSCT, and so on. Consequently, our
analysis might include uncontrolled confounding vari-
ables, even though we performed multivariate analysis.
Another important limitation is the lack of chimerism
data at the time of GF, which prevented us from differ-
entiating GF without donor hematopoiesis from GF
with donor hematopoiesis but poor graft function.In conclusion, this retrospective analysis found
that PBSCT was associated with greater and faster en-
graftment than CBT and led to a significantly better
survival, although it did have a higher rate of acute
GVHD. Considering the difficulty in performing
a randomized controlled trial to compare the effects
of stem cell source in patients with GF, PBSCT with
a conditioning regimen including Flu and an alkylator
may be the preferable salvage therapy, even using
PBSCs from a mismatched related/haploidentical
donor if necessary, in the emergent situation of GF
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